|
|
||||||||
Experimental Studies |
1 From the Department of Radiology and Clinical Research Institute, Seoul National University Hospital and the Institute of Radiation Medicine, Seoul National University Medical Research Center, 28 Yongon-dong, Chongno-gu, Seoul 110-744, Korea (J.W.L., W.K.M., S.J.K., J.H.K., S.H.P., T.J.K., C.J.Y., Y.H.K., K.H.C.); Department of Contrast Media Research, Schering, Berlin, Germany (H.J.W.); Department of Pathology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea (E.Y.C.); and Department of Therapeutic Radiology, Seoul National University Hospital, Korea (S.W.H., W.S.K.). From the 1999 RSNA scientific assembly. Received March 13, 2002; revision requested May 22; final revision received January 12, 2003; accepted February 24. Supported by a grant from Schering, Berlin, Germany. Address correspondence to W.K.M. (e-mail: moonwk@radcom.snu.ac.kr).
PURPOSE: To compare the magnetic resonance (MR) imaging enhancement patterns of a blood pool contrast agent, SH L 643A, with those of gadopentetate dimeglumine in postoperative scars and VX2 carcinomas in rabbits and to compare these enhancement patterns with microvessel density in pathologic specimens.
MATERIALS AND METHODS: Eighteen rabbits with experimentally induced postoperative scars (n = 12) or VX2 carcinoma (n = 6) in the thighs underwent sequential MR imaging first with gadopentetate dimeglumine and then, 24 hours later, with SH L 643A. The enhancement ratios (ie, the ratios of postcontrast to precontrast signal intensity) and the microvessel densities of postoperative scars and VX2 carcinomas were assessed. Differences were tested for by using the Mann-Whitney U and Wilcoxon signed rank tests.
RESULTS: In postoperative scars, enhancement ratios were consistently lower with injection of SH L 643A than with injection of gadopentetate dimeglumine for up to 30 minutes (P < .05). In postoperative scars, mean peak enhancement ratios were 1.29 ± 0.15 (SD) with injection of SH L 643A and 1.61 ± 0.31 with injection of gadopentetate dimeglumine (P < .01). In VX2 carcinomas, the enhancement ratios were not significantly different with injection of SH L 643A than with injection of gadopentetate dimeglumine at all time points. The mean difference between the enhancement ratios of the VX2 carcinomas and postoperative scars was 0.64 ± 0.10 (range, 0.500.77) with SH L 643A and 0.36 ± 0.16 (range, 0.170.66) with gadopentetate dimeglumine (P < .01). The mean microvessel density (in terms of vessels per field of view) was 10.7 ± 5.5 for postoperative scars and 30.0 ± 7.7 for VX2 carcinoma (P < .001).
CONCLUSION: The difference between the enhancement ratios of postoperative scars and VX2 carcinomas with SH L 643A was greater than that with gadopentetate dimeglumine. Enhancement ratios at SH L 643Aenhanced MR imaging corresponded well with microvessel density in postoperative scars and VX2 carcinomas.
© RSNA, 2003
Index terms: Animals Contrast media, comparative studies Experimental study Gadolinium Magnetic resonance (MR), contrast enhancement Magnetic resonance (MR), contrast media Neoplasms, MR
This article has been cited by other articles:
![]() |
N. M. Menezes, E. A. Olear, X. Li, S. A. Connolly, D. Zurakowski, M. Foley, F. Shapiro, and D. Jaramillo Gadolinium-enhanced MR Images of the Growing Piglet Skeleton: Ionic versus Nonionic Contrast Agent. Radiology, May 1, 2006; 239(2): 406 - 414. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Ni, F. Chen, G. Marchal, T. J. Kim, W. K. Moon, and S. N. Goldberg Differentiation of Residual Tumor from Benign Periablational Tissues after Radiofrequency Ablation: The Role of MR Imaging Contrast Agents * Drs Kim and Moon respond: * Dr Goldberg responds: Radiology, November 1, 2005; 237(2): 745 - 749. [Full Text] [PDF] |
||||
![]() |
T. J. Kim, W. K. Moon, J. H. Cha, J. M. Goo, K. H. Lee, K. H. Kim, J. W. Lee, J. G. Han, H.-J. Weinmann, and K. H. Chang VX2 Carcinoma in Rabbits after Radiofrequency Ablation: Comparison of MR Contrast Agents for Help in Differentiating Benign Periablational Enhancement from Residual Tumor Radiology, February 1, 2005; 234(2): 423 - 430. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| RADIOLOGY | RADIOGRAPHICS | RSNA JOURNALS ONLINE |